-
Mashup Score: 1
For most of its existence, the now-defunct biotech startup Theranos operated in so-called “stealth mode” — disclosing little about the science behind its blood-testing device while boldly claiming that it could deliver faster, more convenient, and cheaper diagnostic tests to millions of people anxious to know if they had diabetes, cancer, cardiovascular disease, or scores of other conditions.
Source: www.pewtrusts.orgCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
For most of its existence, the now-defunct biotech startup Theranos operated in so-called “stealth mode” — disclosing little about the science behind its blood-testing device while boldly claiming that it could deliver faster, more convenient, and cheaper diagnostic tests to millions of people anxious to know if they had diabetes, cancer, cardiovascular disease, or scores of other conditions.
Source: www.pewtrusts.orgCategories: General Medicine News, Latest HeadlinesTweet-
“If @US_FDA had required #Theranos to submit its lab developed tests for premarket review, the agency might have been able to shield patients from harm,” says our @RichardsonLiz The #VALIDAct would strengthen oversight to protect Americans. https://t.co/1kFKbHfnHc
-
-
Mashup Score: 1Biden Administration Restores Important Safeguards for Lab-Developed Tests, Though Far Greater Oversight Is Needed - 2 year(s) ago
The Department of Health and Human Services (HHS) recently withdrew an August 2020 policy that severely limited the ability of the Food and Drug Administration to review coronavirus tests and diagnostic tools that are used in the same laboratory where they are made—products known as lab-developed tests (LDTs).
Source: www.pewtrusts.orgCategories: General Medicine News, Latest HeadlinesTweet-
Loopholes in @HHSGov policy allow some lab-developed tests to enter the market without @US_FDA review or registration. The #VALIDAct is a step in the right direction, but still exempts too many products from necessary oversight. https://t.co/ixVf8YggY8
-
-
Mashup Score: 0
The longer Congress waits, the longer patients will remain vulnerable to faulty tests. When it comes to medical tests, we need safety and sunlight, not stealth — and we need it now.
Source: North Jersey Media GroupCategories: General Medicine News, Latest HeadlinesTweet-
#Theranos is not the only company making unsupported marketing claims about the effectiveness of their diagnostic tests. The #VALIDAct could help @US_FDA keep faulty products off the market and protect patients, says our @RichardsonLiz https://t.co/3j6PShvIe2
-
-
Mashup Score: 0
The longer Congress waits, the longer patients will remain vulnerable to faulty tests. When it comes to medical tests, we need safety and sunlight, not stealth — and we need it now.
Source: North Jersey Media GroupCategories: General Medicine News, Latest HeadlinesTweet-
The #Theranos case is just one example of how the lack of transparency and oversight in the diagnostic test industry is harmful to millions of people. If passed, the #VALIDAct could help protect vulnerable Americans, says our @RichardsonLiz https://t.co/3j6PShvIe2
-
#Theranos is not the only company making unsupported marketing claims about the effectiveness of their diagnostic tests. The #VALIDAct could help @US_FDA keep faulty products off the market and protect patients, says our @RichardsonLiz. https://t.co/BWW6rHVUoH